Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 5Malignant Solid Neoplasm 2Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Rectal Neoplasms 1Pelvic Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Malignant Female Reproductive System Neoplasm 1Liposarcoma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colonic Neoplasms 1Childhood Central Nervous System Choriocarcinoma 1Anatomic Stage III Breast Cancer AJCC v8 1Advanced Solid Tumor 1Advanced Malignant Solid Neoplasm 1

Interventions

Injections 26toripalimab 17pembrolizumab 17tislelizumab 12Gemcitabine 8Cisplatin 7spartalizumab 6atezolizumab 6Irinotecan 6Carboplatin 6Paclitaxel 5Oxaliplatin 5Nivolumab 5Leucovorin 5Fluorouracil 5camrelizumab 4Pemetrexed 4Docetaxel 4Cetuximab 4Capecitabine 4trastuzumab deruxtecan 3sintilimab 3olaparib 3lenvatinib 3cediranib 3PM 01183 3Drug Therapy 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × Magnetic Resonance Spectroscopy × Other solid neoplasm × Clear all
NCT05599048 2026-05-27

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

University of California, San Francisco

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡